Stanford



Jay Michael S. Balagtas

Clinical Associate Professor, Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

Oncology

1000 Welch Rd Ste 300 Palo Alto, CA 94304

Tel (650) 723-5535 **Fax** (650) 723-5231

Bio

CLINICAL FOCUS

- Ped Hematology/Oncology
- · Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

· Clinical Associate Professor, Pediatrics - Hematology & Oncology

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
- Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
- Medical Education: New York Medical College Registrar (1998) NY
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)

Research & Scholarship

CLINICAL TRIALS

- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia, Recruiting
- · A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT, Recruiting
- · A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT, Recruiting
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma, Recruiting
- · A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma, Recruiting
- · A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma, Recruiting
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma, Recruiting
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Recruiting
- · Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors, Recruiting

- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement, Recruiting
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery, Recruiting
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma, Recruiting
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors, Recruiting
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Recruiting
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy, Recruiting
- · Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies, Recruiting
- Neuropsychological and Behavioral Testing in Younger Patients With Cancer, Recruiting
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas, Recruiting
- · Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma, Recruiting
- · Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia, Recruiting
- Study of Kidney Tumors in Younger Patients, Recruiting
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors, Recruiting
- Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer, Recruiting
- · A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery, Not Recruiting
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL), Not Recruiting
- · A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia, Not Recruiting
- Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors, Not Recruiting
- · Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia, Not Recruiting
- Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Not Recruiting
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors, Not Recruiting
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET, Not Recruiting
- · Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma, Not Recruiting
- Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma, Not Recruiting
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma, Not Recruiting
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia, Not Recruiting
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Effornithine in Treating Patients With Relapsed or Refractory Neuroblastoma, Not Recruiting
- · Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma, Not Recruiting
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL),
 Not Recruiting
- · Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma, Not Recruiting
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Not Recruiting
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma, Not Recruiting
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder, Not Recruiting

- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial), Not Recruiting
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL), Not Recruiting
- · Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia, Not Recruiting
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations, Not Recruiting

Publications

PUBLICATIONS

 A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia

Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y.

SPRINGER/PLENUM PUBLISHERS.2021: S55

 P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).

Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, et al

LIPPINCOTT WILLIAMS & WILKINS.2021

 P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F., Tran, B., Jeffery, M., Mazhar, D., Huddart, R., Walpole, E., Stevanovic, A. G., Wyld, D., Hanning, et al

WILEY.2020: 205-206

 The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm 2018; 16 (1): 175–80

 Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY

Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y.

2016; 14 (8): 337-41

 Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting PEDIATRIC BLOOD & CANCER

Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.

2015; 62 (11): 2025-2028

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS genetics

Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, et al

2013; 9 (4)

• Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis PEDIATRIC BLOOD & CANCER

Balagtas, J. M., Dahl, G. V.

2012; 58 (1): 101-103

Liposomal amphotericin B associated with severe hyperphosphatemia PEDIATRIC INFECTIOUS DISEASE JOURNAL

Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M.

2008; 27 (1): 77-79